And they quickly dusted off the trial info they inherited from Osiris Therapeutics (and presumably left in the box as another thing to look at if they ever get approval for Prochymal/Remestemcel-L/Ryoncil)?
Looks like a non-plan coming together!
I just hope MSB are only supplying product for COVID-19 trial use, not trying to run it themselves. The right partner seems critical to this not being a time & money sink.
And they quickly dusted off the trial info they inherited from...
-
- There are more pages in this discussion • 19,720 more messages in this thread...
This thread is closed.
You may not reply to this discussion at this time.
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.31 |
Change
0.040(3.16%) |
Mkt cap ! $1.490B | |||
| Open | High | Low | Value | Volume |
| $1.28 | $1.32 | $1.26 | $3.433M | 2.652M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 39558 | $1.30 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.31 | 21776 | 3 |
View Market Depth
| Last trade - 16.10pm 28/10/2024 (20 minute delay) ? |
| MSB (ASX) Chart |